Market capitalization | HKD56.35b |
Enterprise Value | HKD46.88b |
P/E (TTM) P/E ratio | 8.81 |
EV/Sales (TTM) EV/Sales | 1.37 |
P/S ratio (TTM) P/S ratio | 1.65 |
P/B ratio (TTM) P/B ratio | 1.55 |
Dividend yield | 6.29% |
Last dividend (FY23) | HKD0.30 |
Revenue growth (TTM) Revenue growth | -3.20% |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
27 Analysts have issued a CSPC Pharmaceutical Group Limited forecast:
27 Analysts have issued a CSPC Pharmaceutical Group Limited forecast:
Jun '24 |
+/-
%
|
||
Revenue | 34,250 34,250 |
3%
3%
|
|
Gross Profit | 24,319 24,319 |
3%
3%
|
|
EBITDA | 8,978 8,978 |
1%
1%
|
EBIT (Operating Income) EBIT | 7,665 7,665 |
0%
0%
|
Net Profit | 6,413 6,413 |
7%
7%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Hong Kong.
Head office | Hong Kong |
CEO | Cui Zhang |
Employees | 23,500 |
Founded | 1997 |
Website | www.cspc.com.hk |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.